EZHIP Activators
EZHIP (EZH inhibitory protein) functions primarily by antagonizing the polycomb repressive complex 2 (PRC2), thereby affecting chromatin structure and gene expression. Certain small molecule inhibitors that target histone deacetylases (HDACs) contribute to a chromatin landscape that is more open and accessible, a state that is favorable for EZHIP to bind and inhibit its main target, EZH2, within the PRC2 complex. This relaxation of chromatin not only facilitates the inhibitory action of EZHIP but also may enhance its binding efficiency and stability at chromatin sites, reinforcing its role in gene repression. Furthermore, EZHIP's function is complementarily reinforced by the action of specific inhibitors of DNA methyltransferases. By reducing the methylation levels of DNA, these inhibitors can lead to the demethylation of the EZHIP gene promoter, which in turn may result in increased expression of EZHIP itself, thereby amplifying its regulatory impact on gene expression through a feedback mechanism.
In addition to targeting epigenetic modifiers, other compounds that influence cellular signaling pathways may indirectly facilitate the functional activity of EZHIP. Inhibitors of EZH2 and EZH1, which are core components of the PRC2 complex, can synergize with EZHIP's natural inhibitory function, leading to a more pronounced reduction in histone methylation and subsequent gene repression. This reduction in PRC2 activity may allow EZHIP to exert its effects more robustly. Furthermore, specific signaling pathway inhibitors can modulate the cellular environment in a manner that favors EZHIP activity. For instance, inhibition of certain pathways results in altered gene expression patterns that could lead to upregulation of EZHIP or potentiate its suppressive function by influencing the transcriptional milieu.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylyl cyclase increasing cAMP levels in cells. Elevated cAMP may enhance EZHIP protein function by promoting a cellular environment that favors transcriptional repression mechanisms in which EZHIP is implicated. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that leads to an open chromatin state and may enhance EZHIP function by facilitating its binding to chromatin where it inhibits EZH2, thereby enhancing its inhibitory effect on gene expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
DNA methyltransferase inhibitor that causes hypomethylation of DNA, potentially increasing the expression of EZHIP by demethylation of its promoter region, indirectly upregulating its functional activity in the cell. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Histone deacetylase inhibitor that can lead to a relaxed chromatin structure, possibly increasing EZHIP activity by allowing easier access of EZHIP to its targets in the chromatin, thus enhancing its gene repression role. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
DNA methyltransferase inhibitor that can result in DNA demethylation, which may increase EZHIP expression by demethylating its gene promoter, indirectly promoting its functional activity in the cell. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Histone deacetylase inhibitor that can increase the acetylation of histones, potentially facilitating the action of EZHIP by promoting a chromatin environment that is accessible for EZHIP to exert its inhibitory effects. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EZH2 inhibitor that could lead to reduced methylation of histone H3, which may enhance the action of EZHIP by synergistically inhibiting the polycomb repressive complex 2 (PRC2) to which EZH2 belongs. | ||||||
3-Deazaneplanocin, HCl salt | 120964-45-6 | sc-351856 sc-351856A sc-351856B | 1 mg 5 mg 10 mg | $256.00 $612.00 $936.00 | 2 | |
Inhibits S-adenosylhomocysteine hydrolase leading to reduced methylation by EZH2. This may indirectly enhance EZHIP activity by further reducing PRC2 mediated repression when EZHIP is also inhibiting EZH2. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
G9a histone methyltransferase inhibitor which may enhance EZHIP activity by altering histone methylation status and thus influencing chromatin dynamics to favor EZHIP mediated inhibition of EZH2. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
Inhibitor of EZH2 and EZH1, which may augment EZHIP function by further inhibiting the methylation activity of PRC2, enhancing the inhibitory effect of EZHIP on histone methylation and gene expression. | ||||||